Awareness and current knowledge of breast cancer
Breast cancer remains a worldwide public health dilemma and is currently the most common
tumour in the globe. Awareness of breast cancer, public attentiveness, and advancement in …
tumour in the globe. Awareness of breast cancer, public attentiveness, and advancement in …
Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice
BL Riggs, LC Hartmann - New England Journal of Medicine, 2003 - Mass Medical Soc
The selective estrogen-receptor modulators, or SERMs, chemically diverse nonsteroid
compounds, have tertiary structures that permit binding to the estrogen receptor. These …
compounds, have tertiary structures that permit binding to the estrogen receptor. These …
[图书][B] DNA repair and mutagenesis
An essential resource for all scientists researching cellular responses to DNA damage.•
Introduces important new material reflective of the major changes and developments that …
Introduces important new material reflective of the major changes and developments that …
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss, JN Ingle, S Martino, NJ Robert… - … England Journal of …, 2003 - Mass Medical Soc
Background In hormone-dependent breast cancer, five years of postoperative tamoxifen
therapy—but not tamoxifen therapy of longer duration—prolongs disease-free and overall …
therapy—but not tamoxifen therapy of longer duration—prolongs disease-free and overall …
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American …
SS Faubion, LC Larkin, CA Stuenkel, GA Bachmann… - Menopause, 2018 - journals.lww.com
Abstract The objective of The North American Menopause Society (NAMS) and The
International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus …
International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus …
Aromatase inhibitors in breast cancer
IE Smith, M Dowsett - New England Journal of Medicine, 2003 - Mass Medical Soc
Until recently, tamoxifen, a nonsteroidal antiestrogen, was the mainstay of endocrine
treatment of breast cancer. However, new aromatase inhibitors that are many times more …
treatment of breast cancer. However, new aromatase inhibitors that are many times more …
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17
PE Goss, JN Ingle, S Martino, NJ Robert… - Journal of the …, 2005 - academic.oup.com
Background: Most recurrences in women with breast cancer receiving 5 years of adjuvant
tamoxifen occur after 5 years. The MA. 17 trial, which was designed to determine whether …
tamoxifen occur after 5 years. The MA. 17 trial, which was designed to determine whether …
History of aromatase: saga of an important biological mediator and therapeutic target
RJ Santen, H Brodie, ER Simpson, PK Siiteri… - Endocrine …, 2009 - academic.oup.com
Aromatase is the enzyme that catalyzes the conversion of androgens to estrogens. Initial
studies of its enzymatic activity and function took place in an environment focused on …
studies of its enzymatic activity and function took place in an environment focused on …
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
BE Hillner, JN Ingle, RT Chlebowski… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: To update the 2000 ASCO guidelines on the role of bisphosphonates in women
with breast cancer and address the subject of bone health in these women. Results: For …
with breast cancer and address the subject of bone health in these women. Results: For …
Weight loss in breast cancer patient management
RT Chlebowski, E Aiello, A McTiernan - Journal of clinical oncology, 2002 - ascopubs.org
PURPOSE: To systematically review and summarize evidence relevant to obesity and breast
cancer clinical outcome, potential hormonal mediating mechanisms, and the current status …
cancer clinical outcome, potential hormonal mediating mechanisms, and the current status …